









Markets
/
Stocks
/
nasdaq-scni
/

Scinai Immunotherapeutics Ltd

SCNI

1.570USD

+0.010+0.64%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

2.38MMarket Cap

0.63P/E TTM



Scinai Immunotherapeutics Ltd

1.570

+0.010+0.64%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Despite a good stock market performance, the company shows weak fundamentals and technicals, which don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

293 / 506

Overall Ranking

505 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.

Growing

The company is in a growing phase, with the latest annual income totaling USD 658.00K.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD 4.80M.%!(EXTRA int=2)

Overvalued

The company’s latest PE is 0.26, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 391.87K shares, increasing 41.65% quarter-over-quarter.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.81.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 5.62, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.62

Change



Financials

6.20

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.08

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.80

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.95

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.07

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 3.40, which is higher than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is 0.26, which is -70.81% below the recent high of 0.08 and 119.14% above the recent low of -0.05.

Score

Industry at a Glance

Previous score

3.40

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 293/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.03.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 2.69, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 1.75 and the support level at 1.42, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

2.69

Change

-0.23

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(5)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.039

Neutral

RSI(14)

47.300

Neutral

STOCH(KDJ)(9,3,3)

57.927

Neutral

ATR(14)

0.087

Low Volatility

CCI(14)

15.437

Neutral

Williams %R

52.381

Neutral

TRIX(12,20)

-0.224

Sell

StochRSI(14)

17.343

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

1.585

Sell

MA10

1.563

Buy

MA20

1.550

Buy

MA50

1.720

Sell

MA100

2.138

Sell

MA200

2.672

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Yorkville Advisors Global, LP.

93.27K

LCK JNK 1 LLC

80.76K

Stone (Daniel E)

62.40K

Armistice Capital LLC

44.80K

Abalone Asset Management Ltd.

42.54K

+136.35%

Sabby Management, LLC

29.05K

UBS Financial Services, Inc.

14.93K

-36.43%

Reichman (Amir)

8.08K

+236.54%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.14, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.93. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.